Presentation at OPT 2022 to highlight AATD program, including reduction of liver aggregates with repeat AIMer dosing out to 19 weeks Multiple presentations and panel discussions at 3rd Annual RNA ...
Potential best-in-class ADAR editing platform capability continues to advance, with validation of proprietary in vivo modeling system and delivery of in vivo alpha-1 antitrypsin deficiency data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results